In vivo Assay for Diagnosis of Clear Cell Renal Cancer Using I-124 cG250 PET/CT - Part 1

Dr. Daniel Pryma, Assistant Professor of Radiology, and Nuclear Medicine & Molecular Imaging Modality Chief at the Hospital of the University of Pennsylvania, discusses In vivo Assay for Diagnosis of Clear Cell Renal Cancer Using I-124 cG250 PET/CT in the Emerging Technologies Session at the 2010 SNM Annual Meeting. Topics include the physical characteristics and applications of I-124 PET as well as the role of I-124 cG250 in evaluating Clear Cell Renal Cell Carcinoma. I-124 cG250 is an investigational drug and is not currently approved by the FDA and use discussed was performed under IND application. Research has been funded by Wilex AG and IBA Molecular North America, Inc. or its affiliates. Dr. Pryma received reasonable compensation from IBA Molecular North America, Inc. for appearing as part of the panel.

Category:

Science & Technology

Tags:

• IBA
• IBA Molecular
• I-124 cG250
• Renal Cell Carcinoma
• Cancer Diagnosis
• PET/CT
• PET Scan